Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1952 2
1953 2
1954 1
1955 3
1956 4
1957 5
1958 2
1959 2
1960 2
1961 7
1962 17
1963 14
1964 13
1965 16
1966 22
1967 17
1968 18
1969 36
1970 38
1971 34
1972 27
1973 27
1974 39
1975 28
1976 28
1977 46
1978 39
1979 65
1980 64
1981 49
1982 68
1983 96
1984 90
1985 122
1986 119
1987 128
1988 143
1989 146
1990 153
1991 169
1992 179
1993 188
1994 189
1995 182
1996 216
1997 218
1998 236
1999 210
2000 247
2001 230
2002 204
2003 196
2004 178
2005 172
2006 191
2007 206
2008 204
2009 231
2010 198
2011 222
2012 217
2013 234
2014 217
2015 186
2016 194
2017 198
2018 224
2019 242
2020 302
2021 308
2022 290
2023 285
2024 248
2025 15

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,561 results

Results by year

Filters applied: . Clear all
Page 1
STAT6 gain-of-function variant exacerbates multiple allergic symptoms.
Takeuchi I, Yanagi K, Takada S, Uchiyama T, Igarashi A, Motomura K, Hayashi Y, Nagano N, Matsuoka R, Sugiyama H, Yoshioka T, Saito H, Kawai T, Miyaji Y, Inuzuka Y, Matsubara Y, Ohya Y, Shimizu T, Matsumoto K, Arai K, Nomura I, Kaname T, Morita H. Takeuchi I, et al. Among authors: saito h. J Allergy Clin Immunol. 2023 May;151(5):1402-1409.e6. doi: 10.1016/j.jaci.2022.12.802. Epub 2022 Dec 17. J Allergy Clin Immunol. 2023. PMID: 36538978
Laundry detergents and surfactants-induced eosinophilic airway inflammation by increasing IL-33 expression and activating ILC2s.
Saito K, Orimo K, Kubo T, Tamari M, Yamada A, Motomura K, Sugiyama H, Matsuoka R, Nagano N, Hayashi Y, Arae K, Hara M, Ikutani M, Fukuie T, Sudo K, Matsuda A, Ohya Y, Fujieda S, Saito H, Nakae S, Matsumoto K, Akdis CA, Morita H. Saito K, et al. Among authors: saito h. Allergy. 2023 Jul;78(7):1878-1892. doi: 10.1111/all.15762. Epub 2023 May 23. Allergy. 2023. PMID: 37163231
Omics in allergy and asthma.
Saito H, Tamari M, Motomura K, Ikutani M, Nakae S, Matsumoto K, Morita H. Saito H, et al. J Allergy Clin Immunol. 2024 Dec;154(6):1378-1390. doi: 10.1016/j.jaci.2024.09.023. Epub 2024 Oct 9. J Allergy Clin Immunol. 2024. PMID: 39384073 Review.
Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan.
Baba T, Kusumoto M, Kato T, Kurihara Y, Sasaki S, Oikado K, Saito Y, Endo M, Fujiwara Y, Kenmotsu H, Sata M, Takano T, Kato K, Hirata K, Katagiri T, Saito H, Kuwano K. Baba T, et al. Among authors: saito h. Int J Clin Oncol. 2023 Dec;28(12):1585-1596. doi: 10.1007/s10147-023-02414-x. Epub 2023 Oct 3. Int J Clin Oncol. 2023. PMID: 37787866 Free PMC article.
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study.
Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Trukhin D, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Kohlmann M, Lowery C, Mann H, Peters S, Mok TS, Johnson ML. Garon EB, et al. Among authors: saito h. Clin Lung Cancer. 2024 May;25(3):266-273.e5. doi: 10.1016/j.cllc.2024.03.003. Epub 2024 Mar 15. Clin Lung Cancer. 2024. PMID: 38584069 Free article. Clinical Trial. No abstract available.
Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).
Garon EB, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Kim SW, Ursol G, Hussein M, Lim FL, Yang CT, Araujo LH, Saito H, Reinmuth N, Medic N, Mann H, Shi X, Peters S, Mok T, Johnson M. Garon EB, et al. Among authors: saito h. Lung Cancer. 2023 Dec;186:107422. doi: 10.1016/j.lungcan.2023.107422. Epub 2023 Nov 11. Lung Cancer. 2023. PMID: 37992595 Free article. Clinical Trial.
Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, Aoe K, Tsuji T, Takiguchi Y, Takayama K, Komura N, Takiguchi T, Eguchi K. Katakami N, et al. Among authors: saito h. Cancer. 2018 Feb 1;124(3):606-616. doi: 10.1002/cncr.31128. Epub 2017 Dec 4. Cancer. 2018. PMID: 29205286 Free PMC article. Clinical Trial.
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.
Kenmotsu H, Yamamoto N, Misumi T, Yoh K, Saito H, Sugawara S, Yamazaki K, Nakagawa K, Sugio K, Seto T, Toyooka S, Date H, Mitsudomi T, Okamoto I, Yokoi K, Saka H, Okamoto H, Takiguchi Y, Takahashi T, Tsuboi M. Kenmotsu H, et al. Among authors: saito h. J Clin Oncol. 2023 Dec 1;41(34):5242-5246. doi: 10.1200/JCO.23.00179. Epub 2023 Sep 1. J Clin Oncol. 2023. PMID: 37656928 Clinical Trial.
Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.
Writing Committee for the REMAP-CAP Investigators; Lawler PR, Derde LPG, van de Veerdonk FL, McVerry BJ, Huang DT, Berry LR, Lorenzi E, van Kimmenade R, Gommans F, Vaduganathan M, Leaf DE, Baron RM, Kim EY, Frankfurter C, Epelman S, Kwan Y, Grieve R, O'Neill S, Sadique Z, Puskarich M, Marshall JC, Higgins AM, Mouncey PR, Rowan KM, Al-Beidh F, Annane D, Arabi YM, Au C, Beane A, van Bentum-Puijk W, Bonten MJM, Bradbury CA, Brunkhorst FM, Burrell A, Buzgau A, Buxton M, Cecconi M, Cheng AC, Cove M, Detry MA, Estcourt LJ, Ezekowitz J, Fitzgerald M, Gattas D, Godoy LC, Goossens H, Haniffa R, Harrison DA, Hills T, Horvat CM, Ichihara N, Lamontagne F, Linstrum KM, McAuley DF, McGlothlin A, McGuinness SP, McQuilten Z, Murthy S, Nichol AD, Owen DRJ, Parke RL, Parker JC, Pollock KM, Reyes LF, Saito H, Santos MS, Saunders CT, Seymour CW, Shankar-Hari M, Singh V, Turgeon AF, Turner AM, Zarychanski R, Green C, Lewis RJ, Angus DC, Berry S, Gordon AC, McArthur CJ, Webb SA. Writing Committee for the REMAP-CAP Investigators, et al. Among authors: saito h. JAMA. 2023 Apr 11;329(14):1183-1196. doi: 10.1001/jama.2023.4480. JAMA. 2023. PMID: 37039790 Free PMC article. Clinical Trial.
8,561 results